By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asuragen said today that it has obtained a non-exclusive license from Johns Hopkins University to incorporate a BRAF mutation sequence into its molecular diagnostic products.

Terms of the licensing deal includes the use of the mutation, BRAF V600E, as a component in diagnostic test kits and use of it in Asuragen's CLIA laboratory for clinical research and patient testing. Financial terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.